Company / EPS (Diluted)
TherapeuticsMD, Inc. EPS (Diluted) History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$0.99
FY2024
5-year range
-$21.66 / $11.96
FY2020-FY2024
Trend
-108.3%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
EPS (Diluted) has fluctuated over the past 10 years, ranging from $-21.66 in FY2022 to $11.96 in FY2023.
Based on SEC 10-K filings.
-0.99 in FY2024.
Improved from $-21.66 to $-0.99 over the past 2 years.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2024, eps (diluted) decreased 108.3% year-over-year.
- Peak eps (diluted) was recorded in FY2023.
- Lowest eps (diluted) in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.77 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$0.99 | -108.3% |
| FY2023 | $11.96 | +155.2% |
| FY2022 | -$21.66 | -2908.3% |
| FY2021 | -$0.72 | -22.0% |
| FY2020 | -$0.59 | -59.5% |
| FY2019 | -$0.37 | +19.6% |
| FY2018 | -$0.46 | +6.1% |
| FY2017 | -$0.49 | -36.1% |
| FY2016 | -$0.36 | -63.6% |
| FY2015 | -$0.22 | +42.1% |
As of FY2024 · SEC 10-K · Updated Jun 28, 2026